Bitkub Exchange and Bitkub Academy announce a collaboration with Injective to drive the growth of the Web3 finance ecosystem in Thailand

Injective is a Layer 1 blockchain designed to support the creation of Web3 finance applications with 3 main features: speed and efficiency, as Injective can process transactions quickly with low fees, and Injective can also connect to other blockchains such as Ethereum and Solana. In addition, in terms of security, Injective uses a Proof-of-Stake (PoS) consensus mechanism for network security and stability.

Sugrit Phutaviriya, Chief Executive Officer of Bitkub Labs Co., Ltd., said " This collaboration aims to promote understanding of Web3 finance, including DeFi, RWAs, AI finance, etc. Bitkub Exchange and Bitkub Academy will create content to provide knowledge about Injective, blockchain technology, and opportunities in the DeFi ecosystem to Thai users. It also focuses on developing the Web3 community in Thailand through expanding access to DeFi, RWAs and AI. Bitkub Academy will provide knowledge about financial applications built on Injective to expand opportunities for users to access a wider range of efficient financial products and services."

Atthakrit Chimplapibul, Chief Executive Officer of Bitkub Online Co., Ltd., said that Bitkub Exchange recognizes the importance of education and access to Web3 finance. "With this collaboration with Injective, we will focus on providing knowledge and creating opportunities for developers and DeFi users in Thailand through Bitkub Academy and various activities that will be held together. We believe that Injective will be an important platform in developing DeFi, RWA, and AI applications and driving the growth of the digital economy in Thailand and Southeast Asia."

"Injective's collaboration with Bitkub demonstrates our long-term growth and development in Thailand as we continue expanding our footprint in Southeast Asia. We're committed to fostering a vibrant Web3 ecosystem for finance and we envision Bitkub will be instrumental in driving innovation on Injective. We look forward to collaborating with them closely moving forward," added Injective Labs co-founder and CEO, Eric Chen.